UGT1A1基因多态性与伊立替康化疗不良反应及近期疗效关系的临床研究

Clinical study on the relationship between UGT1A1 gene polymorphism and adverse reactions and short-term efficacy of irinotecan chemotherapy

目的研究尿昔二磷酸葡昔酸转移酶1A1*28基因多态性与伊立替康化疗不良反应及近期疗效的关系。方法筛选出我院2013年10月-2016年12月收治的76例恶性肿瘤患者,所有患者均应用含伊立替康的化疗方案治疗,治疗前采集外周血,应用聚合酶链式反应检测UGT1A1*28基因多态性,治疗期间观察患者的不良反应发生情况,治疗后评价近期疗效。结果TA6/6野生型患者出现迟发性腹泻0~2度10例,3~4度6例,总发生率为26.23%(16/61);TA6/7杂合突变型患者出现迟发性腹泻0〜2度6例,3~4度3例,总发生率为60.00%(9/15);TA6/6野生型与TA6/7杂合突变型患者的迟发性腹泻发生率对比,差异有统计学意义(P<0.05)。结论UGT1A1基因多态性与伊立替康化疗不良反应之间存在一定的相关性,与近期疗效无明显相关性。

Objective To study the relationship between uridine diphosphate glucosyltransferase 1A1(UGT1 Al)*6 and UGT1 Al*28 gene polymorphisms and the adverse reactions and short-term efficacy of irinotecan.Methods 76 patients with malignant tumors treated in our hospital from October 2013 to December 2016 were selected.All patients were treated with chemotherapy containing irinotecan.Peripheral blood was collected before treatment,and the gene polymorphisms of UGT1 Al*6 and UGT1 Al*28 were detected by polymerase chain reaction.The occurrence of adverse reactions was observed during treatment,and the short-term curative effect was evaluated after treatment.Results TA6/6 wild-type patients had delayed diarrhea of 0~2 degrees in 10 cases and 3〜4 degrees in 6 cases,with a total incidence of 26.23%(16/61);Patients with TA6/7 heterozygous mutant type had delayed diarrhea of 0~2 degrees in 6 cases and 3 cases with 3~4 degrees,with a total incidence of 60.00%(9/15);The incidence of delayed diarrhea in patients with TA6/6 wild type and TA6/7 heterozygous mutant type was statistically significant(P<0.05).Conclusion UGT1 Al gene polymorphism has a certain correlation with the adverse reactions of irinotecan chemotherapy,but has no significant correlation with the short-term efficacy.